PracticeUpdate Diabetes June 2019

CONTENTS 3

RESEARCH 4 Morbidity and Mortality After Lifestyle Intervention for People With Impaired Glucose Tolerance Comment by Deborah Wexler MD, MSc 5 Risk Factors for Retinopathy in Type 1 Diabetes 6 Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus Comment by James L. Januzzi MD

COVER 4

Morbidity and Mortality After Lifestyle Intervention for People With Impaired Glucose Tolerance Comment by Deborah Wexler MD, MSc

EXPERT OPINION 12 New Data and New Concepts in Managing Triglycerides Interview with Peter Libby MD by Aman Shah MD

14 Obesity and Cardiovascular Disease in Teenagers Interview with Peter Libby MD by Aman Shah MD

7 Canagliflozin Improves Renal Outcomes in Type 2 Diabetes Comment by Steven G. Coca DO, MS 8 Early Intervention for Diabetes Inpatients Decreases Hyperglycemia and Hospital- Acquired Infections Comment by Mary Korytkowski MD and Esra Karslioglu-French MD

CONFERENCE 16 28 th Annual Scientific & Clinical Congress of the American Association of Clinical Endocrinologists By the PracticeUpdate Editorial Team 16 A “Hypo-Triad” and Comprehensive Glucose Paragon Demonstrate Superior Improvement in Glycemic Control 17 Synacthen Testing Identifies Adrenal Insufficiency 18 Proptosis of Thyroid Eye Disease Is Reduced With Teprotumumab 18 Dulaglutide Monotherapy Improves Glycemic Outcomes and Helps Control Body Weight in Obese Adults With Prediabetes 19 Estimation of Von Willebrand Factor a Possible Diagnostic Aid in Identifying CV Risk Factors in Patients With Type 2 Diabetes 20 Stage of Cardiometabolic Disease Proves Predictive of Incident Diabetes

9 Diuretics May Increase Risk of Lower Limb Events in Type 2 Diabetes 10 Deintensification in Older Patients With Type 2 Diabetes Comment by Peter Lin MD, CCFP

VOL. 3 • NO. 2 • 2019